Skip to main content

Table 3 Hazard ratios for overall survival and recurrence free survival in pancreatobiliary type tumours

From: Prognostic and treatment predictive significance of SATB1 and SATB2 expression in pancreatic and periampullary adenocarcinoma

  Pancreatobiliary type
OS RFS
  Univariable Multivariable Univariable Multivariable
Age 0.99 (0.96-1.02) 1.02 (0.99-1.05) 0.98 (0.96-1.01) 0.99 (0.96-1.02)
Sex     
Women     
Men 1.24 (0.80-1.91) 1.02 (0.64-1.64) 1.09 (0.72-1.66) 0.82 (0.52-1.30)
Tumour size     
  1.03 (1.01-1.05) 1.01 (0.99-1.04) 1.04 (1.02-1.05) 1.01 (0.99-1.04)
Tumour grade     
Well-moderate     
Poor 2.50 (1.54-4.05) 2.10 (1.28-3.45) 2.40 (1.50-3.83) 2.35 (1.43-3.84)
Tumour origin     
Ampulla     
Distal bile duct 0.74 (0.40-1.34) 1.02 (0.53-1.98) 1.10 (0.61-1.97) 2.68 (0.33-21.81)
Pancreas 0.88 (0.49-1.60) 1.08 (0.56-2.08) 1.01 (0.56-1.84) 2.26 (0.27-18.81)
T-stage     
T1     
T2 1.93 (0.23-16,04) 0.54 (0.06-5.05) 2.21 (0.27-18.38) 0.61 (0.06-5.75)
T3 3.99 (0.55-28.85) 0.74 (0.09-6.10) 6.43 (0.89-46.43) 1.28 (0.16-10.29)
T4 5.11 (0.67-38.79) 2.36 (0.11-49.41) 5.95 (0.78-45.43) 0.93 (0.11-8.00)
N-stage     
N0     
N1 2.55 (1.49-4.38) 2.49 (1.42-4.38) 2.59 (1.55-4.33) 2.15 (1.22-3.80)
Margin status     
R0     
R1-Rx 4.02 (0.99-16.38) 2.43 (0.59-10.02) 2.71 (0.99-7.44) 2.30 (0.82-6.50)
Perineural     
Pn0     
Pn1 1.97 (1.10-3.53) 1.04 (0.50-2.15) 3.09 (1.66-5.75) 1.80 (0.94-3.46)
Lymphatic vessels     
L0     
L1 1.57 (0.96-2.56) 1.02 (0.57-1.85) 1.85 (1.14-3.01) 1.14 (0.65-2.00)
Blood vessels     
V0     
V1 2.43 (1.56-3.78) 2.53 (1.59-4.03) 2.35 (1.50-3.69) 1.96 (1.21-3.17)
Peripancreatic fat     
Pn0     
Pn1 1.89 (1.05-3.40) 0.94 (0.47-1.90) 2.75 (1.50-5.02) 1.78 (0.94-3.40)
SATB1     
Negative     
Positive 2.11 (1.25-3.56) 1.79 (1.05-3.05) 1.87 (1.10-3.18) 1.54 (0.89-2.66)
Adjuvant chemotherapy     
None/other     
Gemcitabine 0.76 (0.49-1.18) 0.56 (0.35-0.89) 0.98 (0.64-1.49) 0.72 (0.46-1.12)
  1. Bold text indicates significant values.
Back to article page